SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation...

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Targeting the eukaryotic translation initiation factor 4F (eIF4F) complex is a promising strategy to enhance cancer therapies.
• Drug resistance, particularly to BRAF inhibitors (BRAFi), remains a significant challenge in melanoma treatment.

Purpose of the Study:

• To identify and characterize a novel small molecule inhibitor targeting the eIF4F complex.
• To evaluate the efficacy of this inhibitor, SBI-756, against BRAF-resistant and BRAF-independent melanoma models.

Main Methods:

• Identification and characterization of SBI-0640756 (SBI-756) as an inhibitor of eIF4G1 and eIF4F complex assembly.
• Assessment of SBI-756's effects on melanoma cell growth, signaling pathways (AKT, NF-κB), and gene expression.
• In vitro and in vivo studies using various melanoma models (NRAS, BRAF, NF1-mutant) and combination therapy with BRAFi.

Main Results:

• SBI-756 effectively inhibited eIF4F complex assembly independently of mTOR.
• The compound demonstrated efficacy against BRAF-resistant and BRAF-independent melanomas, including NRAS, BRAF, and NF1-mutant types.
• Combination therapy with SBI-756 and BRAFi reduced the formation of BRAFi-resistant tumors in vivo.

Conclusions:

• SBI-756 is a first-in-class eIF4F inhibitor with significant preclinical antitumor activity in melanoma.
• The drug demonstrates potential for overcoming BRAFi resistance and offers a rationale for evaluating its efficacy in other cancers.
• Development of SBI-756 derivatives allows for manipulation of off-target effects while maintaining therapeutic potential.